UNSPSC 51352423: Estradiol and norethisterone acetate

This classification denotes a combination contraceptive drug. The first component of this drug is estradiol, an estrogen with the molecular formula C18H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TI98Z838E, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)- but generally known as estradiol, which bears US NIH Compound Identifier 450. European Medicines Agency schedules Estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07242MIG.

The term ESTRADIOL is an International Non-Proprietary Name. World Health Organization schedules estradiol in its Anatomical Therapeutic Chemical (ATC) Classification. ESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51352423 Estradiol and norethisterone acetate is a Commodity code encompassing hormonal pharmaceutical products that state and local government health agencies and multi-state cooperative purchasing programs source for distribution through public health systems, employee health plans, and Medicaid formularies. Recent solicitations show state and local procurement focused on generic multi-source pharmaceuticals and direct-to-manufacturer prescription programs that bundle this class of product within broader therapeutic categories rather than as standalone line items. Issuing bodies include state health and human services agencies and multi-state cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission are the primary repeat buyers visible in current market activity.

Recent opportunities reflect two procurement models. The Minnesota Department of Administration issued an RFP through MMCAP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers and evaluation weighted heavily on price competitiveness (75 percent), fixed pricing, and EDI capability, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted Request for Information (RFI) No. HHS0017013 on March 27, 2026 (due April 3, 2026) to gather vendor capabilities and market intelligence on establishing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, seeking vendors with direct contracting experience and flexibility on negotiated net pricing models to inform future formal procurement strategy. Activity is concentrated in the upper Midwest and Texas, with MMCAP's multi-state footprint extending procurement reach across participating jurisdictions.